ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 105 filers reported holding ALX ONCOLOGY HLDGS INC in Q2 2021. The put-call ratio across all filers is 0.42 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $152,282 | -40.1% | 25,254 | +10.8% | 0.00% | – |
| Q1 2024 | $254,187 | +284.7% | 22,797 | +413.8% | 0.00% | – |
| Q4 2023 | $66,067 | +188.3% | 4,437 | -7.1% | 0.00% | – |
| Q3 2023 | $22,915 | -57.6% | 4,774 | -33.7% | 0.00% | – |
| Q2 2023 | $54,049 | -50.3% | 7,197 | -70.1% | 0.00% | – |
| Q1 2023 | $108,674 | -60.6% | 24,043 | -1.8% | 0.00% | – |
| Q4 2022 | $275,923 | +18.9% | 24,483 | +1.1% | 0.00% | – |
| Q3 2022 | $232,000 | +17.2% | 24,220 | -1.1% | 0.00% | – |
| Q2 2022 | $198,000 | -19.5% | 24,490 | +68.2% | 0.00% | – |
| Q1 2022 | $246,000 | -30.5% | 14,557 | -11.7% | 0.00% | – |
| Q4 2021 | $354,000 | -70.4% | 16,495 | +2.0% | 0.00% | -100.0% |
| Q3 2021 | $1,194,000 | -10.7% | 16,170 | -33.9% | 0.00% | 0.0% |
| Q2 2021 | $1,337,000 | -31.1% | 24,452 | -7.1% | 0.00% | -33.3% |
| Q1 2021 | $1,940,000 | +52.9% | 26,315 | +78.7% | 0.00% | +50.0% |
| Q4 2020 | $1,269,000 | +132.0% | 14,725 | +1.6% | 0.00% | +100.0% |
| Q3 2020 | $547,000 | – | 14,486 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |